Leaders of the U.S. Senate’s International Narcotics Control Caucus, Sens. Dianne Feinstein (D-CA) and Chuck Grassley (R-IA), introduced a bill entitled the Cannabidiol Research Expansion Act, in the U.S. Senate on May 25, 2017 to expand authorized medical research of cannabidiol (CBD) and to deschedule it from a Schedule I controlled substance. In addition to Feinstein and Grassley, the bill is cosponsored by Senators Dick Durbin (D-Ill.), Thom Tillis (R-N.C.) and Joni Ernst (R-Iowa).
The timing perfectly coincided with the results published in New England Journal of Medicine of a study conducted on Dravet syndrome (suffering from epilepsy) patients concluding that the use of CBD reduced the number of convulsive-seizure frequency.
